-
Frequency Therapeutics' FX-322 Data Published In Peer-Reviewed Journal
Tuesday, February 23, 2021 - 7:12am | 261Frequency Therapeutics Inc (NASDAQ: FREQ) has announced the publication of its lead candidate FX-322 Phase 1/2 study results in Otology & Neurotology. The data was initially announced in April 2019. The data showed hearing improvements in adults with acquired sensorineural...